NantHealth Inc (NYSE:NH)‘s stock had its “buy” rating restated by equities research analysts at Jefferies Group LLC in a research note issued on Monday, June 19th. They presently have a $5.50 price target on the stock, down from their previous price target of $8.00. Jefferies Group LLC’s price target indicates a potential upside of 26.73% from the stock’s current price.
Several other research firms have also issued reports on NH. Canaccord Genuity reiterated a “buy” rating and set a $16.00 price objective on shares of NantHealth in a research note on Friday, February 24th. Zacks Investment Research upgraded NantHealth from a “sell” rating to a “hold” rating in a report on Wednesday, March 8th. FBR & Co set a $13.00 target price on NantHealth and gave the stock a “buy” rating in a report on Saturday, April 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 price target on shares of NantHealth in a research report on Monday, March 6th. Five analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $9.45.
Shares of NantHealth (NYSE:NH) opened at 4.34 on Monday. NantHealth has a 1-year low of $2.94 and a 1-year high of $15.80. The stock has a 50 day moving average of $3.60 and a 200 day moving average of $6.07. The firm’s market cap is $527.83 million.
NantHealth (NYSE:NH) last released its quarterly earnings data on Wednesday, May 10th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.04. NantHealth had a negative return on equity of 42.22% and a negative net margin of 182.66%. The company had revenue of $22.51 million for the quarter, compared to analyst estimates of $29.06 million. During the same quarter in the prior year, the company earned ($0.18) earnings per share. The business’s revenue was up 15.7% compared to the same quarter last year. Equities research analysts anticipate that NantHealth will post ($0.64) earnings per share for the current fiscal year.
WARNING: “NantHealth Inc (NH) Given Buy Rating at Jefferies Group LLC” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://sportsperspectives.com/2017/07/12/nanthealth-inc-nh-earns-buy-rating-from-jefferies-group-llc-updated-updated.html.
Several hedge funds and other institutional investors have recently bought and sold shares of NH. TIAA CREF Investment Management LLC raised its position in NantHealth by 68.6% in the first quarter. TIAA CREF Investment Management LLC now owns 20,200 shares of the company’s stock valued at $100,000 after buying an additional 8,217 shares during the period. Bank of America Corp DE raised its position in NantHealth by 366.4% in the first quarter. Bank of America Corp DE now owns 25,069 shares of the company’s stock valued at $125,000 after buying an additional 19,694 shares during the period. Renaissance Technologies LLC bought a new position in NantHealth during the first quarter valued at $457,000. Capital Impact Advisors LLC bought a new position in NantHealth during the first quarter valued at $583,000. Finally, Highbridge Capital Management LLC bought a new position in NantHealth during the first quarter valued at $998,000.
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.